MedPath

Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases

Completed
Conditions
Myelodysplastic Syndromes
Pulmonary Hypertension
Myeloproliferative Disorder
Interventions
Other: echocardiography, right heart catheterisation
Registration Number
NCT00909467
Lead Sponsor
Medical University of Graz
Brief Summary

Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known. The effects of pulmonary hypertension on the clinical picture and the symptoms of patients in these conditions needs also further exploration. This exploratory study is designed to describe the prevalence of pulmonary hypertension in the population with such hematologic diseases, and the stages of pulmonary hypertension as well its effect on exercise capacity at time of diagnosis.

Detailed Description

For early recognition of pulmonary hypertension exercise doppler echocardiography will be used in all patients. Patients with elevated pulmonary arterial pressure at rest or during exercise (estimated by echocardiography), or with decreased exercise capacity (as a potential sign of pulmonary hypertension) are advised to undergo right heart catheterisation. Cardiopulmonary exercise testing and six-minute walk distance measurement are performed to measure exercise capacity. The described work-up of patients allows precise and objective hemodynamic and clinical evaluation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
86
Inclusion Criteria
  • myelodysplastic disease or myeloproliferative diseases
Exclusion Criteria
  • known pulmonary hypertension
  • relevant pulmonary disease
  • relevant left cardiac or valvular disease
  • recent major operations
  • recent changes in medications
  • relevant anaemia
  • inability to exercise

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
myeloproliferative, -dysplastic diseaseechocardiography, right heart catheterisation-
Primary Outcome Measures
NameTimeMethod
mean pulmonary arterial pressure at rest and during exerciseat baseline and after 1 year
Secondary Outcome Measures
NameTimeMethod
exercise capacityat baseline and after 1 year

Trial Locations

Locations (1)

Medical University of Graz, Pulmonology

🇦🇹

Graz, Austria

© Copyright 2025. All Rights Reserved by MedPath